Ovoca Bio plc

LSE OVB.L

Ovoca Bio plc Free Cash Flow Per Share for the year ending December 31, 2023: USD 0.02

Ovoca Bio plc Free Cash Flow Per Share is USD 0.02 for the year ending December 31, 2023, a 122.94% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Ovoca Bio plc Free Cash Flow Per Share for the year ending December 31, 2022 was USD -0.07, a -7.61% change year over year.
Ovoca Bio plc Free Cash Flow Per Share for the year ending December 31, 2021 was USD -0.06, a -67.08% change year over year.
Ovoca Bio plc Free Cash Flow Per Share for the year ending December 31, 2020 was USD -0.04, a 1.41% change year over year.
Ovoca Bio plc Free Cash Flow Per Share for the year ending December 31, 2019 was USD -0.04, a 3.26% change year over year.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

LSE: OVB.L

Ovoca Bio plc

CEO	Mr. Timothy Rand McCutcheon
IPO Date	Jan. 4, 2000
Location	Ireland
Headquarters	17 Pembroke Street Upper
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

Key trends

Past 5 years